January 5, 2018 – Datavant and DCRI will work closely together in engaging biopharmaceutical partners and implementing innovative approaches to clinical trial design and interpretation, leveraging the power of their combined datasets.
Datavant, a healthcare technology company that aggregates and structures healthcare data to generate actionable insights for clinical trials, has selected Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization, as an analytical partner to accelerate data-driven approaches in drug development, the company announced today.
As Datavant’s Founding Academic Partner, the DCRI will bring deep insights and unique perspectives on data-driven clinical research and access to clinical trial and health system data to augment Datavant’s analytical tools and data assets. The DCRI will gain early access to Datavant’s data and technology. Together, the organizations will create further opportunities to facilitate rapid scaling of best practices in clinical research to improve patient outcomes.
“New clinical insights come from matching the right question with data that can actually inform its answer,” said Michael J. Pencina, DCRI’s director of biostatistics and a professor of biostatistics and bioinformatics at Duke School of Medicine. “The promise of this partnership comes from the blend of the DCRI’s analytic innovations with Datavant’s unique datasets, creating unmatched capacity for discovery.”